logo
Prescient advances cancer drug to unlock value

Prescient advances cancer drug to unlock value

Prescient at critical stage of development with phase 2a trial underway for PTX-100
PTX-100 granted orphan drug and fast track designations by the US FDA, unlocking benefits
Focus on advancing PTX-100 to potential registrational phase 2b trial to open commercial opportunities
Special Report: Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential begin to converge in a defining moment for a biotech company aiming to bring a new therapy to market.
Prescient Therapeutics (ASX:PTX) is in phase 2a trial for its lead compound PTX-100 in patients with rare blood cancer relapsed/refractory Cutaneous T-Cell Lymphoma (r/r CTCL) with the potential for its phase 2b arm to be registrational.
PTX-100 is a first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1). It is believed to be the only GGT-1 inhibitor in the world in clinical development.
The US Food and Drug Administration (FDA) has granted PTX-100 orphan drug designation (ODD) for all T-cell lymphomas and fast-track designation for treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of CTCL.
Fast Track designation provides an expedited pathway to approval, with orphan drug designation offering market exclusivity for a period of seven years in the US.
'The aim is to improve the quality of life for people suffering from this terrible form of cancer and getting them the therapy they need as fast as possible,' CEO James McDonnell said.
'It's also an incentive for larger pharmaceuticals who are looking to add to their portfolio as the drug progresses through clinical development.'
Potential regulatory trial for PTX-100
McDonnell is focused on getting PTX-100 through the phase 2a trial with the potential to make the second phase 2b arm a registration study.
'Fast Track designation opens a dialogue with the FDA for companies to provide ongoing trial updates, instead of a lengthy review at the end, to expedite therapies to patients who desperately need them,' he said.
'All we need to do is replicate the Phase 1b results, if the FDA agrees, they could potentially authorise Phase 2b as a registration study.'
In the phase 1b trial PTX-100 delivered a 45% overall response rate and 64% clinical benefit in T-cell lymphoma, with just 4% serious side effects – well below the 30% benchmark.
'The first step now is to progress Phase 2a where we can define a dose which will also have some efficacy and safety data,' McDonnell said
'The registrational study means we are closer to approval and the momentum for PTX-100 really starts to accelerate and excitement grows on the commercial front.'
Watch: James McDonnell discusses the first US site for the Phase 2a trial of PTX-100.
Eyes on the commercialisation prize
With over 27,000 new TCL cases every year, in eight major centres, PTX is targeting a market worth ~US$1.8 billion.
Commercialisation of PTX-100 will become a key focus for Prescient if it advances to a registrational study, with all options on the table – including partnership, licensing, or taking the drug to market independently.
'We are confident in how PTX-100 could change the lives of thousands, we need the data now to back that confidence and provide the market a clear indication of the value the therapy can provide,' he said.
'PTX-100 is a first-in-class therapy with a unique mechanism of action which has shown very good results in the Phase 1b study.
'These results have exceeded our benchmarks and compare well to the available therapies on efficacy, duration and a safety perspective.'
McDonnell said that Dimerix (ASX:DXB) was a great example of what a potential commercial pathway could look like for Prescient if Phase 2b became a registrational trial.
Dimerix is advancing its lead candidate DMX-200 through the ACTION3 phase 3 trial for the rare kidney disease FSGS and has secured four regional licensing agreements to drive commercialisation.
'They were able to take orphan drug designated therapy DMX-200, which is currently in a phase 3 registration study, into significant licensing agreements worth approximately $1.4 billion,' he said.
'Dimerix have highlighted how these milestones, FDA designation and registrational study, can open commercialisation opportunities and drive value creation.'
McDonnell said in biotech it often comes down to two questions with the first being: can you get a product to market? The second is: what kind of market is waiting at the end?
Phase 2 trials usually provide clearer insights into a drug's potential, with data readouts serving as critical indicators that can drive value inflection points.
Source: Prescient Therapeutics
A series of upcoming catalyst
Investors have plenty to watch out for in H2 CY25, with Prescient advancing its phase 2a study.
'We are excited for the release, once we reach 20 patients, of the initial data from the dose optimisation committee review, which will be a key event in determining the next steps for development of PTX-100,' McDonnell said.
A share purchase plan aimed at raising $7 million to support Prescient's clinical program closed on July 25.
'There are several milestones we are looking to hit in the coming months and if we can potentially get that Phase 2b into a registration study we can start to shift our focus toward commercialisation opportunities,' McDonnell said.
This article was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Paralysed woman writes her name for the first time in 20 years after having Elon Musk Neuralink chip implant surgery
Paralysed woman writes her name for the first time in 20 years after having Elon Musk Neuralink chip implant surgery

News.com.au

time3 hours ago

  • News.com.au

Paralysed woman writes her name for the first time in 20 years after having Elon Musk Neuralink chip implant surgery

A woman paralysed since 2005 has written her name for the first time in two decades thanks to Elon Musk. Audrey Crews became the first woman in the world to undergo surgery earlier this month receiving Mr Musk's Neuralink chip implant, allowing her to control a computer with her mind. Ms Crews recently took to X to show the world how she was able to select a coloured cursor on screen and sign her name through telepathy. She showed off how she could also draw pictures, scroll with a mouse and use a keyboard just by thinking. 'I tried writing my name for the first time in 20 years. I'm working on it. Lol,' she said. 'I am the first woman in the world to do this.' Ms Crews was left a quadriplegic at age 16 following a car accident that left the vertebrae in her neck permanently damaged. By 2016, tech billionaire Musk co-founded Neuralink with expert in neuroscience in hopes of using AI tech to treat brain disorders. Three years later he revealed the N1 chip, which is placed on the brain to translate electrical signals into tasks. Ms Crews is just the ninth recipient. She underwent surgery at the University of Miami Health Centre where surgeons place over 100 threads, thinner than human hair into her motor cortex after drilling through her skull. The implant, roughly the size of a 10 cent coin, sends those signals to a linked computer or smartphone with Neuralink's software via Bluetooth, allowing patients with paralysis or neurological conditions to communicate digitally. 'Imagine your pointer finger is left click and the cursor is with your wrist, without physically doing it. Just a normal day using telepathy,' she said. Ms Crews has also started taking requests of what to draw next, recently sketching a cat, a sun and a tree after being asked by X users. She's also able to play simulation games testing her accuracy and speed by having her cursor track points on the screen as they change. Mr Musk even replied to a post about Ms Crews' story. 'She is controlling her computer just by thinking. Most people don't realise this is possible,' he said. While the technology won't allow her to regain movement of her limbs, the advancement has so far impressed Ms Crews who hopes to make the most of it by writing a book about her experiences. The chip is powered by a small battery that charges wirelessly. Asked if she ever imagined being able to communicate in such a way again, Ms Crews had one response: 'Not in all my wildest dreams, but the future is here.'

Are Australians at risk from lifting the restrictions on US beef imports?
Are Australians at risk from lifting the restrictions on US beef imports?

SBS Australia

time7 hours ago

  • SBS Australia

Are Australians at risk from lifting the restrictions on US beef imports?

"Australia bans — and they're wonderful people, and wonderful everything — but they ban American beef. Yet we imported $3 billion of Australian beef from them just last year alone. They won't take any of our beef. They don't want it because they don't want it to affect their farmers and, you know what I don't blame them, but we're doing the same thing.' When United States President Donald Trump singled out Australia's ban on US beef imports, Prime Minister Anthony Albanese said he would never compromise on protecting farmers or biosecurity. "We have made it very clear to the United States that we will not compromise on biosecurity. We will not weaken the measures that protect our farmers and producers from the risks of disease or contamination. Indeed, we've made it a priority to strengthen biosecurity, because one of the things that makes Australian food and fibre the best in the world is a people everywhere, know that it stands for quality. It also stands for safety." Now, ahead of the tariff deadline on August 1, Australia's restrictions on US beef imports have been dropped. But the government says the timing of the decision is a coincidence, and has nothing to do with Donald Trump. Minister for Agriculture, Julie Collins, says a review into the US beef ban began in 2015 under the Coalition Government. "This decision has been purely based on science and a rigorous assessment by my department. Biosecurity risk assessment process is very robust and I have faith in the officials in my department to do this appropriately. These are experts in the field. Australia's biosecurity system is world-renowned for a reason and this assessment has now been completed." In 2019, Australia changed restrictions to allow beef imports from cattle traceably born, raised, and slaughtered in the US. In practice, however, the ongoing biosecurity rules meant that only a small amount of beef, largely shelf-stable products, were imported from the US. "We are assured that the supply chain and traceability and the safety of any food coming into Australia is safe. The US, of course, has been able to bring beef into Australia since 2019. Our farmers, are of course, are exporting already to the United States. We're exporting over four billion dollars' worth of beef to the United States presently and our farmers are a net beneficiary of our two-way trading system." So, why was the ban imposed in the first place? And should Australians be concerned about eating beef imported from the US? In 2003, Australia placed restrictions on the import of US beef in response to an outbreak of bovine spongiform encephalopathy, more commonly known as Mad Cow Disease. Humans cannot contract mad cow disease, though in rare cases they can develop a variant which leads to dementia and premature death. However, the Australian food regulator deems US beef is low-risk. Trade Minister Don Farrell says the government would not compromise standards for trade. "We have not made any compromise and we certainly have not compromised Australia's strict biosecurity laws. This has been a process that's been underway for the last 10 years. It's now come to a completion and it's appropriate that we announce the results of that inquiry. But at no stage do we risk our terrific biosecurity standards for any trade arrangement." One key concern remaining after 2019 was that Mexico's livestock tracking system could inadvertently allow beef from disease-affected regions to enter Australia. However, the government says the review has found that the US Department of Agriculture protocols for beef imported from Canada and Mexico now address Australia's biosecurity concerns. Mark Thomas, the Chair of the Western Beef Association, says it's unclear how effective the US tracking system is. "Well, we implement an NIL system, as they call it, so any animal that's born on your property has a electronic tag, and that same tag is scanned and transferred whenever that animal leaves your property, all the way through to sort of slaughter. So an animal that's been slaughtered, they can go back and work out where that animal has been over its lifetime. I am unsure how quickly America can get up to speed. However, it's taken many, many years for Australia to implement that system and make sure that it works efficiently." Despite government assurances, National Party leader David Littleproud is among critics calling for an independent examination into the matter. "The government has not provided or released the protocols on which the beef from the U.S could be imported into this country. Those are the legal requirements that an importer would have to meet to bring beef from the United States into Australia, that was from Mexico or Canada. The fact they haven't done that raises serious concerns to me around how this decision has been made and the timing of it. If it was well planned, the department would be able to provide me with those details. They have not. I think the prudent way forward is to have an independent scientific panel review the department's decision and the protocols when they came out." Along with concerns about the spread of disease, there are also concerns about differing US regulations around the use of hormones and antibiotics on cattle. While some cattle in the US are given approved natural or synthetic hormones to help them grow, the US Food and Drug Administration regulates these, and experts say they are in extremely low levels. US beef, according to both Australian and US officials, is safe to eat, but is it better than Australian beef? Evangeline Mantzioris is the Program Director of Nutrition and Food Sciences at the University of South Australia. She says the diet of an animal impacts the nutritional value of the meat. "What it comes down to is the type of feed that the animals are given. So in the US they tend to be grain-fed whilst here in Australia, they tend to be grass-fed, and that produces differences in the way that the body of the cow handles it and in the way that they make and lay down fat in their body. The other thing that might make a slight difference is also the genetics of the cows. So assuming it's the same breed of cow, we expect grain-fed to lead to more fat in the meat compared to grass-fed." Studies show that grass-fed beef can be 30 to 75 per cent lower in fat than grain-fed. Grass-fed is also reported to have higher levels of beneficial Omega-3 fats, up to five times more antioxidants, and slightly higher protein, with some studies also indicating lower cholesterol. So, for consumers, choosing between local and imported beef will mostly come down to personal preference rather than health concerns. Dr Mantzioris says while the differences aren't major, grass-fed beef is the best option. "So if we combine all of those different components of the beef that we've looked at, overall grass fed beef, which is what we have in Australia, is the healthier option." But what about Australian farmers? When Australia lifted the ban, Donald Trump wrote on social media that the US was now going to sell 'so much beef' to Australia. Australia is the second largest exporter of beef products in the world. And while Australians are some of the highest per capita consumers of beef products, our relatively small population means we have a lot left to export. Mark Thomas says he isn't too worried about competing with U-S products. "Well, I suppose, from a from a cattle perspective's point of view, our only concern would be if we thought that US beef was going to compete with our own product here in Australia, and I don't believe that that is going to do so based on the price of cattle in the US over a longer period of time and considering their cattle numbers compared to what we have here in Australia." In fact, US cattle stocks have been in decline for two decades. The United States is the second largest importer of beef globally and cattle stocks in the country are the lowest they've been since the 1950's. The US Department of Agriculture says beef prices have increased by 8 per cent since the start of 2025, with one kilogram of beef costing around AU$30.. Mark Thomas says with beef shortages in the United States, it's unlikely the Australian market is going to be flooded with imported US beef. "Well, currently, there's a lot of Australian beef going into the US market, purely because they need it. At the moment, cattle prices in the US are just quoting a heavy steer close to $5 whereas that same animal in Australia is only going for $2.50 so how can they purchase an animal for $5 a kilo? Process it, send it to the other side of the world and expect to compete with the product that we have here?" While beef prices have been increasing in the United States, Australian beef exports broke an all-time monthly record in June. And the biggest buyer was, that's right, the United States. In New York, Stew Leonard Junior is the CEO of a grocery chain. He says he gets grass-fed beef from Australia and plans on splitting the tariff cost with his supplier. "We are a huge meat purchaser, and it's mainly the US. So you know, there could be some, that's one of our trains going by up there, okay, for the kids right there, they love that. But one of the things we don't get a lot from Australia, the only thing we do get is our grass-fed beef. They sell beautiful grass- fed beef in Australia. That's being tariffed a little bit. We're splitting that tariff with our supplier. We don't really buy beef from Canada or Mexico or Argentina."

ASX Resources Quarterly Wrap: Lithium bounce could boost these junior explorers
ASX Resources Quarterly Wrap: Lithium bounce could boost these junior explorers

News.com.au

time8 hours ago

  • News.com.au

ASX Resources Quarterly Wrap: Lithium bounce could boost these junior explorers

Electric vehicle sales surge 30% sparking lithium price boost Major lithium miners climb on expectation of rising demand Anson defines maiden Green River Resource in June quarter Burgeoning global electric vehicle sales – up 30% to date according to Canaccord Genuity – have boosted lithium prices on expectations that demand for the battery metal will advance in lockstep. Price reporting agency Fastmarkets had last Tuesday assessed 6% Li2O – the benchmark for the spodumene concentrate mined by WA producers – at US$760/t, a significant gain from the low of US$610/t on June 23, 2025. This is due to rising futures prices in China and improved buying interest from battery makers, as well as the closure of a number of Chinese operations on environmental grounds. Lithium carbonate prices have also risen in the same period from US$8050/t to US$8550/t. This has proved to be a boon for lithium producers with Mineral Resources (ASX:MIN) rising 37% since July 1, 2025, to $29.80 while Pilbara Minerals (ASX:PLS) has put on 23.2% to $1.67 in the same period. Juniors have also gained from the improved lithium sentiment, and here are some companies that have been progressing operations during the June 2025 quarter… Anson Resources (ASX:ASN) During this period, Anson defined maiden JORC resources of 103,000t of contained lithium carbonate equivalent at its Green River project in Utah. The estimate is based on the drilling on the Bosydaba #1 well and could be increased in the near-term through the re-entry of the historical Mt Fuel-Skyline Geyser 1-25 well in the current quarter. Anson has also added 100 strategic placer claims to increase the Green River landholding by 10%. About 28% of these fall within the Area of Influence and will be included in subsequent JORC Mineral Resource estimates upgrades. Further resource upgrades could come from recent swabbing programs returning consistently higher assay values. Other steps taken by the company include entering into a non-binding memorandum of understanding with POSCO Holdings to collaborate on the construction of a direct lithium extraction demonstration plant, and working with the Utah state government to develop a new, lower state royalty rate scaled from 1% to 5% based upon market conditions compared to the previous flat rate of 5%. Delta Lithium (ASX:DLI) During the June 2025 quarter, Delta spun out its Mt Ida gold asset into new ASX-listed company Ballard Mining (ASX:BM1) to focus on its lithium assets. It also expanded the footprint of its Yinnetharra lithium and tantalum project through two transactions – the acquisition of Minerals 260's (ASX:MI6) Aston project and Zeus Resources' (ASX:ZEU) Mortimer Hills project. These have added 1778km2 to Yinnetharra, taking the total land package up to over 3100km2. Both assets have highly prospective tenure, are under-explored and host compelling targets for immediate exploration. Delta has also updated resources at Yinnetharra to 21.9Mt at 1% Li2O and 39.4Mt at 102ppm tantalum. The company has started systematic geochemical sampling and mapping over priority areas with passive seismic surveying to follow this year along with drill testing at Jamesons and adjacent prospects along the Leake Springs meta-sediment package in the following quarter. First Lithium (ASX:FL1) First Lithium continues to work closely with the Mali government to finalise renewals for its Gouna and Faraba permits. Discussions have also indicated the maiden resource will be finalised with results released in the current quarter. The Mali government had earlier this year announced plans to partially lift the suspension of mining permits that had been in place since September 2022 from March 15, 2025. The company has received a letter from the National Director of Geology and Mines in Mali confirming geophysical survey work can continue on both permits while direct meetings have confirmed the requirements for the licence renewal process. Chariot Corporation (ASX:CC9) Meanwhile, Chariot acquired a 66.7% interest in one of the largest hard rock lithium portfolios in Nigeria for US$1.5m in cash and 42 million shares in the company. The assets cover ~254km2 across the Fonlo, Gbugbu, Iganna, and Saki projects in Oyo and Kwara states. These contain a mix of licence types: exploration licences (ELs) for large-scale exploration and small-scale mining leases (SSMLs) over known mineralisation which provide Chariot with an opportunity to investigate fast-track development options. Notably, the Nigerian tenements have historically produced several thousand tonnes of spodumene concentrate for export to Chinese customers between 2021 and 2024, validating both the quality of mineralisation and existence of buyers. Chariot plans to start systematic exploration across the Nigerian portfolio, with initial field programs underway and first drilling targeted for late 2025. Separately, the company is awaiting results from Phase 2 drilling at its Black Mountain lithium project in Wyoming. It is also monitoring developments at neighbouring projects to its Resurgent project in the McDermitt Caldera on the border of Nevada and southern Oregon.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store